Chemotherapy + MAPK inhibitors + ARSENIC TRIOXIDE for neuroblastoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 18 Apr 2025: Trial registered, NCT06933394

The trials

NCT06933394: Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma

State
Under way
Phase
Phase 2
People
92 planned
Started
1 May 2025
Primary completion
1 May 2031
Arms
Experiment group
Results
None posted
  1. 18 Apr 2025: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Trial registered

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.